Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare lysosomal storage disease, and the severe, early onset form of sialidosis characterized by a progressively severe mucopolysaccharidosis-like phenotype (coarse facies, dysostosis multiplex, hepatosplenomegaly), macular cherry-red spots as well as psychomotor and developmental delay. ST-2 displays a broad spectrum of clinical severity with antenatal/congenital, infantile and juvenile presentations.
Features include always present findings: Reduced tissue neuraminidase activity; and very common findings: Kidney disease (nephropathy), Ascites, Inguinal hernia, and Short stature and others. 59 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 12 | Severe intellectual disability, Seizure, Slurred speech |
Kidneys and urinary system | 6 | Kidney disease (nephropathy), Nephrotic syndrome, Reduced kidney function (renal insufficiency) |
Bones and joints | 6 | Bone-marrow foam cells, Bone and joint problems (abnormality of the skeletal system), Skeletal muscle atrophy |
Muscles | 5 | Low muscle tone (hypotonia), Generalized hypotonia, Muscle weakness |
Eyes | 5 | Cherry red spot of the macula, Cataract, Nystagmus |
Digestive system | 3 | Ascites, Enlarged liver (hepatomegaly), Enlarged spleen (splenomegaly) |
Head and neck | 3 | Abnormal facial shape, Facial edema, Coarse facial features |
Heart and blood vessels | 3 | Pericardial effusion, Enlarged heart (cardiomegaly), Heart muscle disease (cardiomyopathy) |
Ears | 2 | Inner ear hearing loss (sensorineural hearing impairment), Hearing loss (hearing impairment) |
Metabolism | 1 | Abnormality of metabolism/homeostasis |
Growth and development | 1 | Short stature |
Pregnancy and birth | 1 | Hydrops fetalis |
Blood and immune system | 1 | Enlarged spleen (splenomegaly) |
Lungs and breathing | 1 | Dyspnea |
NEU1 encodes neuraminidase 1 (415 aa). Catalyzes the removal of sialic acid (N-acetylneuraminic acid) moieties from glycoproteins and glycolipids. To be active, it is strictly dependent on its presence in the multienzyme complex.
Sialidosis type 2 is associated with mutations in the NEU1 gene on chromosome 6.
NEU1 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
Genetic testing for NEU1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for sialidosis type 2 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 19 very common features, 7 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
3 clinical trials registered, 1 recruiting. Interventions under study include other interventions and biologic therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
28 publications have been identified in PubMed for sialidosis type 2. Research spans Review / Meta-Analysis (36%), Basic Science / Preclinical (29%), and Case Report / Case Series (21%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 10 | 36% |
Laboratory research | 8 | 29% |
Patient case studies | 6 | 21% |
New treatment approaches | 2 | 7% |
Testing and diagnosis research | 1 | 4% |
Disease patterns and progression | 1 | 4% |
Ada E (2026). [PMID: 41665755](https://pubmed.ncbi.nlm.nih.gov/41665755/). *Cell Tissue Res*. [Basic Science / Preclinical]
Lee JJ (2026). [PMID: 41582713](https://pubmed.ncbi.nlm.nih.gov/41582713/). *Dis Model Mech*. [Basic Science / Preclinical]
Sun XL (2026). [PMID: 41352710](https://pubmed.ncbi.nlm.nih.gov/41352710/). *Life Sci*. [Review / Meta-Analysis]
Itoh K (2026). [PMID: 41917397](https://pubmed.ncbi.nlm.nih.gov/41917397/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Cherian A (2026). [PMID: 41817056](https://pubmed.ncbi.nlm.nih.gov/41817056/). *Neurol India*. [Review / Meta-Analysis]
Gburek-Augustat J (2026). [PMID: 41665440](https://pubmed.ncbi.nlm.nih.gov/41665440/). *Epilepsia Open*. [Review / Meta-Analysis]
Jeffreys N (2026). [PMID: 41490796](https://pubmed.ncbi.nlm.nih.gov/41490796/). *J Inherit Metab Dis*. [Case Report / Case Series]
Tew TB (2026). [PMID: 42011900](https://pubmed.ncbi.nlm.nih.gov/42011900/). *J Inherit Metab Dis*. [Diagnostic / Biomarker]
Casazza K (2026). [PMID: 42008923](https://pubmed.ncbi.nlm.nih.gov/42008923/). *Mol Genet Metab*. [Review / Meta-Analysis]
Zhou X (2025). [PMID: 40468413](https://pubmed.ncbi.nlm.nih.gov/40468413/). *Acta Epileptol*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center